INTRODUCTION: Glioblastoma multiforme (GBM) is the most malignant primary brain tumor in adults. Recent whole-genome studies revealed novel GBM prognostic biomarkers such as mutations in metabolic enzyme IDH-isocitrate dehydrogenases (IDH1 and IDH2). The distinctive mutation IDH1 R132H was uncovered to be a strong prognostic biomarker for glioma patients. We investigated the prognostic role of IDH1 R132H mutation in GBM patients in West Bohemia. METHODS: The IDH1 R132H mutation was assessed by the RT-PCR in the tumor samples from 45 GBM patients treated in the Faculty Hospital in Pilsen and was correlated with the progression free and overall survival. RESULTS: The IDH1 R132H mutation was identified in 20 from 44 GBM tumor samples (45.4%). The majority of mutated tumors were secondary GBMs (16 in 18, 89.9%). Low frequency of IDH1 mutations was observed in primary GBMs (4 in 26, 15.3%). Patients with IDH R132H mutation had longer PFS, 136 versus 51 days (P < 0.021, Wilcoxon), and OS, 270 versus 130 days (P < 0.024, Wilcoxon test). SUMMARY: The prognostic value of IDH1 R132H mutation in GBM patients was verified. Patients with mutation had significantly longer PFS and OS than patients with wild-type IDH1 and suffered more likely from secondary GBMs.

Central Immunoanalytical Laboratory Faculty Hospital in Pilsen Dr E Benese 13 305 99 Pilsen Czech Republic

Department of Biology Faculty of Medicine in Pilsen Charles University Prague Husova 3 301 66 Pilsen Czech Republic

Department of Histology and Embryology and Biomedical Centre Faculty of Medicine in Pilsen Charles University Prague Husova 3 301 66 Pilsen Czech Republic

Department of Neurology Faculty of Medicine in Pilsen Charles University Prague Husova 3 301 66 Pilsen Czech Republic ; Faculty Hospital in Pilsen Alej Svobody 80 304 60 Pilsen Czech Republic

Zobrazit více v PubMed

Krex D, Klink B, Hartmann C, et al. Long-term survival with glioblastoma multiforme. Brain. 2007;130(10):2596–2606. PubMed

Dolecek TA, Propp JM, Stroup NE, Kruchko C. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005–2009. Neuro-Oncology. 2012;14(supplement 5):v1–v49. PubMed PMC

Polivka J, Jr., Polivka J, Rohan V, Topolcan O, Ferda J. New molecularly targeted therapies for glioblastoma multiforme. Anticancer Research. 2012;32:2935–2946. PubMed

Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme. Science. 2008;321(5897):1807–1812. PubMed PMC

Cairns RA, Mak TW. Oncogenic isocitrate dehydrogenase mutations: mechanisms, models, and clinical opportunities. Cancer Discovery. 2013;3:730–741. PubMed

Sanson M, Marie Y, Paris S, et al. Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. Journal of Clinical Oncology. 2009;27(25):4150–4154. PubMed

Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. The New England Journal of Medicine. 2009;360(8):765–773. PubMed PMC

Dunn GP, Andronesi OC, Cahill DP. From genomics to the clinic: biological and translational insights of mutant IDH1/2 in glioma. Neurosurgical Focus. 2013;34, article E2 PubMed

Hartmann C, Meyer J, Balss J, et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathologica. 2009;118(4):469–474. PubMed

Turcan S, Rohle D, Goenka A, et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature. 2012;483(7390):479–483. PubMed PMC

Hartmann C, Hentschel B, Wick W, et al. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathologica. 2010;120(6):707–718. PubMed

Polivka J, Polivka J, Jr., Rohan V, Topolcan O. Glioblastoma multiforme—a review of pathogenesis, biomarkers and therapeutic perspectives. Česká a Slovenská Neurologie a Neurochirurgie. 2013;76(109):575–583.

Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–674. PubMed

Forbes SA, Bindal N, Bamford S, et al. COSMIC: mining complete cancer genomes in the catalogue of somatic mutations in cancer. Nucleic Acids Research. 2011;39(1):D945–D950. PubMed PMC

Dang L, White DW, Gross S, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 2010;465, article 966 PubMed PMC

Loenarz C, Schofield CJ. Expanding chemical biology of 2-oxoglutarate oxygenases. Nature Chemical Biology. 2008;4(3):152–156. PubMed

Lu C, Ward PS, Kapoor GS, et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature. 2012;483(7390):474–478. PubMed PMC

Ye D, Ma S, Xiong Y, Guan KL. R-2-hydroxyglutarate as the key effector of IDH mutations promoting oncogenesis. Cancer Cell. 2013;23:274–276. PubMed PMC

Weiler M, Wick W. Molecular predictors of outcome in low-grade glioma. Current Opinion in Neurology. 2012;25:767–773. PubMed

Zou P, Xu H, Chen P, et al. IDH1/IDH2 mutations define the prognosis and molecular profiles of patients with gliomas: a meta-analysis. PLoS ONE. 2013;8e68782 PubMed PMC

Kim J, DeBerardinis RJ. Cancer. Silencing a metabolic oncogene. Science. 2013;340:558–559. PubMed PMC

Ichimura K, Pearson DM, Kocialkowski S, et al. IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Neuro-Oncology. 2009;11(4):341–347. PubMed PMC

Killela PJ, Reitman ZJ, Jiao Y, et al. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proceedings of the National Academy of Sciences of the United States of America. 2013;110:6021–6026. PubMed PMC

IDH Mutation Analysis in Glioma Patients by CADMA Compared with SNaPshot Assay and two Immunohistochemical Methods

IDH1 mutation is associated with lower expression of VEGF but not microvessel formation in glioblastoma multiforme

Current status of biomarker research in neurology